Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Pick a Campervan That Offers Something else for Less - 2Rights group: At least 2,500 deaths during protest crackdown in Iran
- 3Instructions to Clean and Really focus on Your Lab Precious stone
- 4Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- 5The most effective method to Pick The Right Speakers
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- UK forecast to face weaker growth and higher inflation from Iran war
- Europe’s EV Boom Was Real in 2025. The Real Fight Starts In 2026
- What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- British Columbia's Secret Lakeside Town With Hot Springs Is 'An Oasis Of Arts, Culture And Relaxation'
- OECD: Iran war dampening global growth
